Natif de Baie-Comeau, où habitent plusieurs membres de sa famille, le Dr Jean-Philippe Julien fait partie de l’édition 2021 du Top 40 des Canadiens de moins de 40 ans aux réalisations exceptionnelles. Photo courtoisie
From left to right: Illan Kramer, Akshita Vincent, Derek Newton, Leah Cowen, Andrea Carfi, Patricia Gauthier, Kavisha Jayasundara and Shehzad Iqbal (photo by Johnny Guatto)

The University of Toronto and Moderna, Inc. – known for its mRNA-based COVID-19 vaccine – plan to work together to develop new tools to prevent and treat infectious diseases.

Guided by a partnership framework agreement, the U.S. biotechnology firm will collaborate with U of T researchers who are working across a wide range of fields, including molecular genetics, biomedical engineering, biochemistry and beyond.

The research partnership – Moderna’s first with a Canadian university – was announced Monday during a visit by company executives to U of T’s St. George campus.

Leah Cowen, U of T’s vice-president, research and innovation, and strategic initiatives, said U of T is excited to work alongside Moderna to protect society from current and future health threats.

“Today we are delighted to announce that Moderna is partnering with U of T, and is keen to do so because Moderna recognizes that there is nowhere else in the world where you can find expertise at scale like you can at U of T,” Cowen said during an executive meeting of Moderna and U of T leaders at Simcoe Hall.

“It’s not every day that an opportunity presents to combine a world class life-sciences research community and a disruptive biological innovator. We are proud to say that today is one such day.”

Cowen touted the diversity found at U of T – which reflects that of Toronto, the province and Canada as a whole – as a key strength of our research ecosystem.

The company’s research pipeline also includes development candidates for several other mRNA-based vaccines and therapies – with several clinical trials and discovery programs already underway.

Patricia Gauthier, Moderna’s country general manager in Canada, said the firm is looking forward to tapping U of T’s interdisciplinary expertise to accelerate shared priorities in medical research.

Read the full story on U of T News

Prof. Leah Cowen

Vice-President, Research and Innovation, and Strategic Initiatives, UofT
Canada Research Chair in Microbial Genomics & Infectious Disease
Co-Director of the CIFAR Fungal Kingdom: Threats & Opportunities program